MindWalk Secures $30M Unsecured Credit Line to Fuel Biologics Push — MindWalk Holdings Corp.

Event summary

MindWalk Holdings Corp. secured a binding commitment for a $30M unsecured revolving credit facility with Sanabil (Cayman).
The facility carries a 7.00% fixed annual interest rate, no financial covenants, and no equity conversion features.
Funds will support biologics programs, commercial expansion, and working capital over a 36-month term.
MindWalk chose debt financing over equity to avoid dilution at current share prices.

The big picture

MindWalk’s decision to opt for debt financing over equity reflects a strategic preference to avoid dilution in a challenging market environment. The $30M facility underscores the company’s focus on scaling its biologics programs and expanding its commercial footprint, aligning with broader industry trends toward AI-driven biotech innovation. The absence of financial covenants or equity conversion features provides MindWalk with operational flexibility, but the burden of servicing the debt will be a key factor in its financial health moving forward.

What we're watching

Debt Management: Whether MindWalk can service and repay the $30M facility without straining its cash runway.
Commercial Adoption: The pace at which ReefIQ and LensAI gain traction in the pharmaceutical industry.
Market Valuation: How the debt financing impacts MindWalk’s market valuation and investor perception.